WebAug 2, 2024 · This type I interferon receptor antagonist demonstrated early and sustained benefits for people with moderate to severe systemic lupus erythematosus. The U.S. Food and Drug Administration (FDA) has … WebOn August 2, 2024, the U.S. FDA approved anifrolumab, brand name Saphnelo (AstraZeneca Pharmaceuticals LP), for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
DailyMed - SAPHNELO- anifrolumab injection, solution
WebSAPHNELO is a prescription medicine used to treat adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines. It is not known if SAPHNELO is effective in patients with severe active lupus nephritis or severe active central nervous system lupus. WebThe most common side effects of SAPHNELO include: Upper respiratory infections. Bronchitis. Infusion reactions. Shingles (herpes zoster) Cough. Infusion reactions can happen at the time of the infusion or shortly after, symptoms may include headache, nausea, vomiting, feeling tired or weak (fatigue), and dizziness. birdo character
Lupus Foundation of America Celebrates FDA …
WebFeb 16, 2024 · cough or hoarseness. cough producing mucus. fever. flushing. headache. lower back or side pain. nausea and vomiting. painful blisters on the trunk of the body. painful or difficult urination. WebSaphnelo 300 Mg/2 Ml (150 Mg/Ml) Intravenous Solution Immunosuppressive - Interferon Inhibitor, Monoclonal Ab - Uses, Side Effects, and More Generic Name: anifrolumab-fnia . WebThe AstraZeneca Access 360™ program provides personal support and resources to help streamline access and reimbursement for select AstraZeneca medicines, including SAPHNELO. These resources include the Benefits Investigations Report, the Denial Management Guide, and the Peer-to-Peer resource. Explore Access 360. damien o\u0027reilly rte wife